Press Room - Sanofi US News

Menu

Media Room Menu

Month Year

Month Year

Aug 8, 2019

Provention Bio Initiates Phase 1b/2a PREVAIL Clinical Trial Evaluating PRV-3279 in Lupus

-Bispecific Diabody Designed to Intercept B-Cell Mediated Autoimmune Diseases-
Aug 6, 2019

Dupixent® (dupilumab) showed positive topline results in Phase 3 trial of children aged 6 to 11 years with severe atopic dermatitis

U.S. FDA submission for children planned for 4Q 2019
Aug 6, 2019

Provention Bio Reports Second Quarter 2019 Financial Results

PRV-031 Granted Breakthrough Therapy Designation for the Delay or Prevention of Clinical Type 1 Diabetes in At-Risk Individuals
Aug 5, 2019

Provention Bio Announces Breakthrough Therapy Designation for Teplizumab (PRV-031) for the Prevention or Delay of Clinical Type 1 Diabetes in At-Risk Individuals
Jul 29, 2019

Sanofi delivered solid growth in Q2 2019
- Photos 4

Show per page

Print
Email page
RSS

You are about to leave www.sanofi.us

If you wish to continue to this external website, click Proceed. It is provided for information only. Sanofi assumes no responsibility for the information presented on this website.